Clinical Trial Update: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy of tislelizumab and spartalizumab across multiple cancers with PD-1 high mRNA expression; the trial is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Esophageal Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Lung Adenocarcinoma
• Melanoma
• Pancreatic Adenocarcinoma
• Urothelial Carcinoma

Drugs mentioned

• Spartalizumab (spartalizumab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: MSI-H Colorectal Cancer, Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING